ISSN 1662-4009 (online)

ey0018.4-5 | Growth Hormone Therapy: Safety | ESPEYB18

4.5. Long-term safety of growth hormone treatment in childhood: two Large observational studies: nordiNet IOS and ANSWER

L Savendahl , M Polak , P Backeljauw , JC Blair , BS Miller , TR Rohrer , A Hokken-Koelega , A Pietropoli , N Kelepouris , J Ross

J Clin Endocrinol Metab. 2021 May 13;106(6):1728–1741. doi: 10.1210/clinem/dgab080. PMID: 33571362This report gathered data from two large observational studies (NordiNet International Outcome Study and ANSWER Program) aimed at assessing the incidence of adverse drug reactions (ADRs), serious adverse events (SAEs), and their relation with rhGH dose. The whole study cohort included 37,7...

ey0018.10-9 | (1) | ESPEYB18

10.9. Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case-control ancillary study

ME Miettinen , S Niinisto , I Erlund , D Cuthbertson , AM Nucci , J Honkanen , O Vaarala , H Hyoty , JP Krischer , M Knip

Diabetologia. 2020;63(4):780–787. doi: 10.1007/s00125-019-05077-4.This multicenter multinational study, in children with high genetic risk of T1D, identified an association between lower serum 25-hydroxyvitamin D (25OHD) concentrations and subsequent appearance of islet autoimmunity or T1D.The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary ...

ey0019.4-3 | Important for clinical practice | ESPEYB19

4.3. Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation

C Jagodzinski , S Mueller , R Kluck , K Froede , L Pavicic , J Gellermann , D Mueller , U Querfeld , D Haffner , M Zivicnjak

Pediatr Nephrol, 2022. 37(4): p. 859-869 PMID: 34542703Brief Summary: This prospective observational cohort study investigated growth rate after kidney transplant in children with chronic kidney disease (CKD) and growth failure, who received or did not receive rhGH treatment before transplantation. Patients pre-treated with rhGH showed better growth rates with taller height SDS at 7 years after transplantation. Positive effects of pre-transplant...

ey0019.4-9 | New Perspectives | ESPEYB19

4.9. High prevalence of variants in skeletal dysplasia associated genes in individuals with short stature and minor skeletal anomalies

L Sentchordi-Montane , S Benito-Sanz , M Aza-Carmona , F Diaz-Gonzalez , S Modamio-Hoybjor , la Torre C De , J Nevado , P Ruiz-Ocana , C Bezanilla-Lopez , P Prieto , P Bahillo-Curieses , A Carcavilla , I Mulero-Collantes , AC Barreda-Bonis , J Cruz-Rojo , J Ramirez-Fernandez , de la Vega JA Bermudez , AM Travess , J Gonzalez de Buitrago Amigo , A Del Pozo , E Vallespin , M Solis , C Goetz , A Campos-Barros , F Santos-Simarro , I Gonzalez-Casado , P Ros-Perez , M Parron-Pajares , KE Heath

Eur J Endocrinol, 2021. 185(5): p. 691-705. PMID: 34516402Brief Summary: This study evaluated the prevalence of genetic variants in children with idiopathic short stature (ISS) using next-generation sequencing (NGS). Heterozygous variants in known genes involved in skeletal physiology were identified in almost 20% of children. The use of advanced genetic analysis techniques will lead to an increased identification of new genetic variants, expand...

ey0019.5-10 | Translational highlights | ESPEYB19

5.10. INZ-701 prevents ectopic tissue calcification and restores bone architecture and growth in ENPP1-deficient mice

Z Cheng , K O'Brien , J Howe , C Sullivan , D Schrier , A Lynch , S Jungles , Y Sabbagh , D Thompson

J Bone Miner Res. 2021 Aug;36(8):1594-1604.Abstract: https://pubmed-ncbi-nlm-nih-gov/33900645/In Brief: Enzyme replacement therapy with human ENPP1-Fc protein in Enpp1asj/asj mice, a murine model of ENPP1 deficiency, restored circulating levels of PPi, prevented clinical manifestations and decreased mortality.Commentary: ENPP1 deficiency causes gen...

ey0019.5-14 | Translational highlights | ESPEYB19

5.14. Fibrillin-1 deficiency in the outer perichondrium causes longitudinal bone overgrowth in mice with Marfan syndrome

L Sedes , E Wondimu , B Crockett , J Hansen , A Cantalupo , K Asano , R Iyengar , D.B Rifkin , S Smaldone , F Ramirez

Hum Mol Genet ddac107 (2022)Abstract: https://pubmed.ncbi.nlm.nih.gov/35567544/In Brief: Disproportionate tall stature represents a hallmark feature of Marfan syndrome, although specific mechanisms underlying linear bone overgrowth are unclear. This study used an ex vivo model system to identify dysregulation of TGFβ-binding proteins in the outer perichondrium as causative for the bon...

ey0019.10-11 | Complications and comorbidities | ESPEYB19

10.11. Thirty-Year time trends in diabetic retinopathy and macular edema in youth with type 1 diabetes

DW Allen , G Liew , YH Cho , A Pryke , J Cusumano , S Hing , AK Chan , ME Craig , KC Donaghue

Diabetes Care. 2022 May 20:dc211652. https://pubmed.ncbi.nlm.nih.gov/35594057/Brief Summary: This longitudinal study reports trends in diabetic retinopathy (DR) and macular edema (DME) across 3 decades: 1990-1999, 2000-2009, 2010-2019, in a large Australian cohort of 2404 adolescents with type 1 diabetes (T1D). The prevalence of DR decreased between 1990-1999 and 2000-2009, from 40 to 21%, ...

ey0019.13-6 | Improving access to healthcare in pediatric endocrinology and diabetes | ESPEYB19

13.6. Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean region: it takes a village…

A Rowlands , A Deeb , A Ladjouze , RT Hamza , SA Musa , J Raza , F Jennane , A Abu-Libdeh , JP Chanoine , the GPED CAH Working Group

jchanoine@cw.bc.ca BMJ Global Health 2021;6:e007195. doi: 10.1136/bmjgh-2021-007195Brief Summary: This review found that access to oral fludrocortisone and hydrocortisone remains suboptimal in the WHO Eastern Mediterranean Region. Improvement requires a collaboration between health professionals, families of patients, health authorities, pharmaceutica...

ey0019.14-11 | Risk and Outcome | ESPEYB19

14.11. SGA-born adults with postnatal catch-up have a persistently unfavourable metabolic health profile and increased adiposity at age 32 years

Goedegebuure Wesley J. , Van der Steen Manouk , Smeets Carolina CJ , Kerkhof Gerthe F , Hokken-Koelega Anita CS

European Journal of Endocrinology (2022)187:15–26 doi: 10.1530/EJE-21-1130Brief Summary: This study, PROGRAM32, investigated 287 adults mean age 32 years who had participated 10 years earlier in the PROGRAM study on the metabolic and cardiovascular consequences of low birth weight (LBW). The aim was to investigate the adverse metabolic profile of being small for gestational age with spontane...

ey0019.15-9 | Assorted Conditions | ESPEYB19

15.9. Genetic insights into biological mechanisms governing human ovarian ageing

KS Ruth , FR Day , J Hussain , A Martinez-Marchal , CE Aiken , A Azad , DJ Thompson , et al.

Nature. 2021;596(7872):393-7. doi: 10.1038/s41586-021-03779-7.PubMed ID: 34349265Brief summary: This study analysed genome-wide association array (GWAS) data on ~200 000 women of European ancestry to identify 290 separate genetic signals associated with normal variation in age at natural menopause (ANM). Experimental alterations of key identified genes in mouse models confirmed their impac...